4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells In vitro

F. Boccardo, D. Medicina, F. Galmozzi, L. Emionite, M. Lo Casto

Research output: Contribution to journalArticle

Abstract

Background: The present study was aimed at investigating the effects of the co-administration of 4-OH Tamoxifen (4HT) and bicalutamide (BIC) on the human prostate cancer cell line LNCaP in vitro. Materials and Methods: The LNCaP FGC prostate cancer cell line was grown in vitro within a three-dimensional matrix formed by collagen gel under dihydrotestosterone (DHT) (0.1 nM) stimulation. Cells were incubated in the presence either of BIC at escalating concentrations (1 nM; 100 nM; 10 μM) or 4HT Tamoxifen (10 nM; 100 nM) or both compounds at the different concentrations studied. The cells were incubated for 144 hours, and growth was evaluated in non trypsinised cells by crystal violet vital dye staining assay. Results: BIC appeared to exert a dose-dependent inhibitory action, with the maximum inhibitory effect achieved by the 10 μM concentration. A comparable inhibitory effect was also observed after exposure to 4HT at both doses tested. No statistically significant interference was observed when BIC was combined with 4HT. Conclusion: 4HT, even at the higher concentration employed here, showed no major interference with the inhibitory effects of BIC.

Original languageEnglish
Pages (from-to)4277-4280
Number of pages4
JournalAnticancer Research
Volume25
Issue number6 B
Publication statusPublished - Nov 2005

Fingerprint

Tamoxifen
Prostatic Neoplasms
Gentian Violet
Cell Line
Dihydrotestosterone
In Vitro Techniques
bicalutamide
Coloring Agents
Collagen
Gels
Staining and Labeling
Growth

Keywords

  • 4-OH tamoxifen
  • Bicalutamide
  • LNCaP cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells In vitro. / Boccardo, F.; Medicina, D.; Galmozzi, F.; Emionite, L.; Lo Casto, M.

In: Anticancer Research, Vol. 25, No. 6 B, 11.2005, p. 4277-4280.

Research output: Contribution to journalArticle

Boccardo, F, Medicina, D, Galmozzi, F, Emionite, L & Lo Casto, M 2005, '4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells In vitro', Anticancer Research, vol. 25, no. 6 B, pp. 4277-4280.
Boccardo, F. ; Medicina, D. ; Galmozzi, F. ; Emionite, L. ; Lo Casto, M. / 4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells In vitro. In: Anticancer Research. 2005 ; Vol. 25, No. 6 B. pp. 4277-4280.
@article{c595346957174a619fc06ce51c0a908a,
title = "4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells In vitro",
abstract = "Background: The present study was aimed at investigating the effects of the co-administration of 4-OH Tamoxifen (4HT) and bicalutamide (BIC) on the human prostate cancer cell line LNCaP in vitro. Materials and Methods: The LNCaP FGC prostate cancer cell line was grown in vitro within a three-dimensional matrix formed by collagen gel under dihydrotestosterone (DHT) (0.1 nM) stimulation. Cells were incubated in the presence either of BIC at escalating concentrations (1 nM; 100 nM; 10 μM) or 4HT Tamoxifen (10 nM; 100 nM) or both compounds at the different concentrations studied. The cells were incubated for 144 hours, and growth was evaluated in non trypsinised cells by crystal violet vital dye staining assay. Results: BIC appeared to exert a dose-dependent inhibitory action, with the maximum inhibitory effect achieved by the 10 μM concentration. A comparable inhibitory effect was also observed after exposure to 4HT at both doses tested. No statistically significant interference was observed when BIC was combined with 4HT. Conclusion: 4HT, even at the higher concentration employed here, showed no major interference with the inhibitory effects of BIC.",
keywords = "4-OH tamoxifen, Bicalutamide, LNCaP cells",
author = "F. Boccardo and D. Medicina and F. Galmozzi and L. Emionite and {Lo Casto}, M.",
year = "2005",
month = "11",
language = "English",
volume = "25",
pages = "4277--4280",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - 4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells In vitro

AU - Boccardo, F.

AU - Medicina, D.

AU - Galmozzi, F.

AU - Emionite, L.

AU - Lo Casto, M.

PY - 2005/11

Y1 - 2005/11

N2 - Background: The present study was aimed at investigating the effects of the co-administration of 4-OH Tamoxifen (4HT) and bicalutamide (BIC) on the human prostate cancer cell line LNCaP in vitro. Materials and Methods: The LNCaP FGC prostate cancer cell line was grown in vitro within a three-dimensional matrix formed by collagen gel under dihydrotestosterone (DHT) (0.1 nM) stimulation. Cells were incubated in the presence either of BIC at escalating concentrations (1 nM; 100 nM; 10 μM) or 4HT Tamoxifen (10 nM; 100 nM) or both compounds at the different concentrations studied. The cells were incubated for 144 hours, and growth was evaluated in non trypsinised cells by crystal violet vital dye staining assay. Results: BIC appeared to exert a dose-dependent inhibitory action, with the maximum inhibitory effect achieved by the 10 μM concentration. A comparable inhibitory effect was also observed after exposure to 4HT at both doses tested. No statistically significant interference was observed when BIC was combined with 4HT. Conclusion: 4HT, even at the higher concentration employed here, showed no major interference with the inhibitory effects of BIC.

AB - Background: The present study was aimed at investigating the effects of the co-administration of 4-OH Tamoxifen (4HT) and bicalutamide (BIC) on the human prostate cancer cell line LNCaP in vitro. Materials and Methods: The LNCaP FGC prostate cancer cell line was grown in vitro within a three-dimensional matrix formed by collagen gel under dihydrotestosterone (DHT) (0.1 nM) stimulation. Cells were incubated in the presence either of BIC at escalating concentrations (1 nM; 100 nM; 10 μM) or 4HT Tamoxifen (10 nM; 100 nM) or both compounds at the different concentrations studied. The cells were incubated for 144 hours, and growth was evaluated in non trypsinised cells by crystal violet vital dye staining assay. Results: BIC appeared to exert a dose-dependent inhibitory action, with the maximum inhibitory effect achieved by the 10 μM concentration. A comparable inhibitory effect was also observed after exposure to 4HT at both doses tested. No statistically significant interference was observed when BIC was combined with 4HT. Conclusion: 4HT, even at the higher concentration employed here, showed no major interference with the inhibitory effects of BIC.

KW - 4-OH tamoxifen

KW - Bicalutamide

KW - LNCaP cells

UR - http://www.scopus.com/inward/record.url?scp=27944472574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944472574&partnerID=8YFLogxK

M3 - Article

C2 - 16309228

AN - SCOPUS:27944472574

VL - 25

SP - 4277

EP - 4280

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -